Aligos Therapeutics ALGS
NASDAQ ALGS
$2.10 +0.12 (+6.06%)
At close: Nov 13, 2026 · 4:00 PM EST

Aligos Therapeutics (ALGS) Return on Sales [ROS] (2019 - 2026)

Updated

Aligos Therapeutics (ALGS) posted Return on Sales [ROS] of -773.50% for Q3 2026, up 3053.90 percentage points from -3827.40% a year earlier and up 1338.64 percentage points from the prior quarter.

Analysis

Aligos Therapeutics (ALGS) Return on Sales [ROS] (2019 - 2026) Analysis & Trends

For the trailing twelve months through Sep 30, 2026, Return on Sales [ROS] at Aligos Therapeutics was -1244.18%, up 2062.50 percentage points year-over-year; for FY2025, it was -4024.93%, down 1555.98 percentage points from FY2024.

  • Annual Return on Sales [ROS] has declined for three consecutive years, though with a five-year change of +3126.68 percentage points (FY2020 to FY2025).
  • In prior years, Aligos Therapeutics' Return on Sales [ROS] was -2468.96% in FY2024 (-1525.21 pp), -943.75% in FY2023 (-242.08 pp), -701.66% in FY2022 (+2242.16 pp) and -2943.82% in FY2021 (+4207.79 pp).
  • The Q3 2026 figure stands as the highest quarterly Return on Sales [ROS] since Q2 2023.
  • On a year-over-year basis, Return on Sales [ROS] increased in three of the last eight quarters, with an average year-over-year change of -1021.77 percentage points.
  • The strongest year-over-year quarter for Return on Sales [ROS] in the past five years was Q4 2022, with a gain of 9698.78 percentage points; the weakest was Q4 2025, with a drop of 9514.46 percentage points.
  • According to Business Quant data, Return on Sales [ROS] for the three prior quarters was -2112.14% (Q2 2026), -951.55% (Q1 2026) and -12907.69% (Q4 2025).
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) ROS (Qtr)
1 Eli Lilly 1,359.75 Bn 1,333.37 Bn 20.46 Bn 34.46%
2 Johnson & Johnson 688.76 Bn 608.62 Bn 17.30 Bn 24.35%
3 AbbVie 521.69 Bn 489.75 Bn 13.12 Bn 36.01%
4 Merck 364.31 Bn 327.31 Bn 13.19 Bn 30.74%
5 Novartis Ag 306.35 Bn 279.93 Bn - -
6 Astrazeneca 285.96 Bn 259.56 Bn 13.26 Bn 29.12%
7 Amgen 251.88 Bn 203.53 Bn 7.58 Bn 35.79%
8 Gilead Sciences 208.59 Bn 183.61 Bn 6.73 Bn 41.71%
9 Pfizer 164.73 Bn 112.38 Bn 12.56 Bn 32.98%
10 Aligos Therapeutics 21.97 Mn -314.86 Mn - -773.50%
Historic Data

Historic Data

Download Data
DateValue
Sep 30, 2026 -773.50%
Jun 30, 2026 -2,112.14%
Mar 31, 2026 -951.55%
Dec 31, 2025 -12,907.69%
Sep 30, 2025 -3,827.40%
Jun 30, 2025 -1,924.04%
Mar 31, 2025 -6,187.46%
Dec 31, 2024 -3,393.23%
Sep 30, 2024 -1,610.48%
Jun 30, 2024 -2,489.54%
Mar 31, 2024 -3,176.66%
Dec 31, 2023 -1,294.03%
Sep 30, 2023 -885.38%
Jun 30, 2023 -445.76%
Mar 31, 2023 -925.98%
Dec 31, 2022 -641.28%
Sep 30, 2022 -461.47%
Jun 30, 2022 -552.21%
Mar 31, 2022 -1,383.00%
Dec 31, 2021 -10,340.05%
API Access

Aligos Therapeutics Return on Sales [ROS] API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=return-on-sales-%5Bros%5D&ticker=ALGS&period=max&api_key=YOUR_API_KEY